ILMN - Illumina - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090
Sequencing Instruments, Genomic Analysis Kits, Whole-Genome Sequencing Kits
Illumina, Inc. is a leading provider of innovative solutions for genetic and genomic analysis, operating globally with a presence in the United States, Singapore, the United Kingdom, and other international markets. The company's business is divided into two main segments: Core Illumina and GRAIL.
The Core Illumina segment offers a range of sequencing and array-based instruments, consumables, and kits that enable researchers and clinicians to analyze genetic and genomic data. These products include reagents, flow cells, and library preparation tools, as well as whole-genome sequencing kits that can sequence entire genomes of varying size and complexity. Additionally, the company provides targeted resequencing kits that allow for the analysis of specific genes, RNA, or other genomic regions of interest.
Beyond its product offerings, Illumina also provides a range of services, including whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. One of its flagship products is Galleri, a multi-cancer early detection test that has the potential to revolutionize cancer diagnosis. The company is also actively developing solutions to accelerate cancer diagnoses, detect minimal residual disease through blood-based testing, and support other post-diagnostic applications.
Illumina's customer base is diverse and includes genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through partnerships with life-science distributors.
Founded in 1998, Illumina is headquartered in San Diego, California, and has established itself as a pioneer in the field of genomics. With a strong commitment to innovation and customer support, the company continues to drive advancements in genetic and genomic analysis, ultimately improving human health and well-being.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ILMN Stock Overview
Market Cap in USD | 19,885m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC SubIndustry | Life Sciences Tools & Services |
TER | 0.00% |
IPO / Inception | 2000-07-28 |
ILMN Stock Ratings
Growth 5y | -56.7 |
Fundamental | 50.4 |
Dividend | 0.00 |
Rel. Performance vs Sector | -0.86 |
Analysts | 3.96/5 |
Fair Price Momentum | 110.08 USD |
Fair Price DCF | 55.75 USD |
ILMN Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ILMN Growth Ratios
Growth 12m | -14.89% |
Growth Correlation 12m | -19% |
Growth Correlation 3m | 89% |
CAGR 5y | -15.66% |
CAGR/Mean DD 5y | -0.39 |
Sharpe Ratio 12m | -0.47 |
Alpha vs SP500 12m | -42.79 |
Beta vs SP500 5y weekly | 1.10 |
ValueRay RSI | 53.20 |
Volatility GJR Garch 1y | 39.29% |
Price / SMA 50 | 2.31% |
Price / SMA 200 | 2.28% |
Current Volume | 2246.4k |
Average Volume 20d | 1482.1k |
External Links for ILMN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of September 13, 2024, the stock is trading at USD 124.83 with a total of 2,246,400 shares traded.
Over the past week, the price has changed by -2.70%, over one month by +1.37%, over three months by +19.61% and over the past year by -11.20%.
According to ValueRays Forecast Model, ILMN Illumina will be worth about 121.9 in September 2025. The stock is currently trading at 124.83. This means that the stock has a potential downside of -2.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 148.3 | 18.8 |
Analysts Target Price | 186.4 | 49.4 |
ValueRay Target Price | 121.9 | -2.32 |